Biogen Idec cuts a deal to boost cancer offerings
234249
Moving to strengthen its offerings to treat cancer, Biogen Idec Inc. of Cambridge yesterday signed a deal to license tumor-killing technology from ImmunoGen Inc.
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
152308
General Electric Co. , the world's biggest maker of medical-imaging machines, and Abbott Laboratories broke off an agreement for GE to buy some of Abbott's diagnostics units for $8.13 billion.
337666
SAN FRANCISCO -- Billionaire investor Carl C. Icahn was given clearance by US antitrust regulators to purchase shares in Biogen Idec Inc., the world's biggest maker of drugs for multiple sclerosis.
753120
Carl Icahn, the billionaire investor who took over TWA in the 1980s and has battled executives at Motorola , Time Warner , and other iconic corporations, now appears to have Biogen Idec Inc. in his crosshairs.
335265
Biogen Idec Inc.  said on Thursday that fourth-quarter earnings rose on higher sales of its cancer and multiple sclerosis drugs.
459907
Introgen Therapeutics Inc., a gene  therapy company, on Thursday said its experimental breast  cancer treatment showed promise in a mid-stage clinical trial,  driving its shares up 24 percent.
455403
The biopharma announces a dramatic shift following the failure of its lead drug.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
176562
By Karen Attwood  The Dutch healthcare and chemicals group Akzo Nobel ditched plans to float its biopharmaceutical division in favour of a sale yesterday, triggering speculation it would next make a move on the chemicals group Imperial Chemical Industries.
708424
Elan Corp. PLC of Ireland yesterday denied it was involved in merger talks with Biogen Idec Inc. of Cambridge, seeking to squelch rumors of a possible deal just prior to the anticipated approval of Antegren, the two firms' treatment for multiple sclerosis.
267375
Investors in the biotechnology company Biogen Idec announced Wednesday that it had not received any definitive offers after putting itself up for sale two months ago.
567020
U.S. drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros (&#36;10.6 billion) for Irish peer Elan, a newspaper reported on Sunday.
225228
BOSTON (CBS.MW) - Shares of Genentech were halted on Monday as the company announced that its oncology drug Avastin had been shown to extend the lives of some patients stricken with advanced colorectal cancer.
139290
Biogen Idec Inc., the third-biggest US biotechnology company, reported a fourth-quarter profit of $48.4 million, helped by sales of its Avonex and Tysabri multiple-sclerosis treatments. Net income was 14 cents a share compared with a net loss of $990.6 million, or $4.03, a year earlier, the Cambridge company said. Revenue almost doubled to $586 million. Biogen is counting on Tysabri, ...
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
515177
BRITAINâS biotech industry yesterday attacked government plans to cut the price of medicines by 7 per cent next year. The Bioindustry Association said talks between the Government and âBig